×
  • 業(ye) 務谘詢

    中國:

    Email: marketing@boboandtiantian.com

    業(ye) 務谘詢專(zhuan) 線:400-780-8018

    (僅(jin) 限服務谘詢,其他事宜請撥打川沙總部電話)

    川沙總部電話: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在線留言×
點擊切換
Customer Center
客戶中心

研究人員設計合成STAT3和HDAC雙通路抑製劑用於治療實體腫瘤,PK實驗通過必威betway网址進行

2023-07-05
|
訪問量:

56.png

The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. 

Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity. 

The pharmacokinetic experiment in SD Rats was carried out by Medicilon.

Reference:

相關新聞
×
搜索驗證
點擊切換